Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a pioneering biopharmaceutical company dedicated to discovering and developing next-generation gene and cellular therapies in the United States. Specializing in disease-modifying therapeutics, Precigen has been at the forefront of genetic engineering and synthetic biology solutions. The company excels in creating innovative therapies for some of the most challenging diseases in areas such as immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's core technologies include:
- UltraVector® Platform: This platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.
- UltraCAR-T® Cell Therapies: These therapies address limitations of conventional CAR-T therapies by improving in vivo CAR-T expansion and persistence, adding safety features, and reducing manufacturing costs.
- AdenoVerse™ Technology Platform: A library of engineered adenovector serotypes, including gorilla adenovectors, which is used for gene delivery, and modulating immune responses.
- RheoSwitch® Inducible Gene Switch: This technology allows for precise control over gene expression, making therapies safer and more efficient.
Recent achievements include the Phase 2 pivotal study data for PRGN-2012 in treating recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. The study showcased promising results, with 51% of patients achieving Complete Response, defined as no need for surgical interventions in the 12-month period following treatment.
Precigen is also actively developing UltraCAR-T therapies, which have demonstrated significant preliminary efficacy and safety advantages over existing CAR-T therapies. These therapies are currently being evaluated in clinical trials for various hematological and solid tumors.
Financially, Precigen has shown resilience, focusing on sound fiscal management while advancing its clinical pipeline. Despite experiencing fluctuations in research expenses and revenues, the company remains committed to achieving its milestones and maintaining a strong balance sheet.
Precigen's business model involves commercializing its technologies through collaborations with industry partners who possess specialized expertise, development resources, and sales capabilities. This collaborative approach enables Precigen to bring new and improved products to market efficiently.
For the latest updates on Precigen's innovative gene and cell therapies, visit their official website and follow them on social media platforms like X (formerly Twitter), LinkedIn, and YouTube.
Precigen (PGEN) reported Q3 2024 financial results and key updates. The company completed pre-BLA meetings with FDA and is aligned for Q4 2024 rolling BLA submission of PRGN-2012 for RRP under accelerated approval. Commercial and manufacturing preparations are underway for potential 2025 launch. Q3 net loss was $24.0 million ($0.09 per share) compared to $19.8 million ($0.08 per share) in Q3 2023. The company raised $30.9 million through a public offering in August 2024 and implemented strategic prioritization, including 20% workforce reduction, to focus on PRGN-2012 commercialization.
Precigen (Nasdaq: PGEN) has announced its participation in the Stifel 2024 Healthcare Conference in New York. Helen Sabzevari, PhD, President and CEO, will engage in a fireside chat on Tuesday, November 19, 2024, from 10:55 to 11:25 AM ET. The conference is scheduled for November 18-19, 2024.
Precigen is a discovery and clinical stage biopharmaceutical company focused on developing next-generation gene and cell therapies. The company specializes in precision technology targeting immuno-oncology, autoimmune disorders, and infectious diseases, working to create affordable biotherapeutics through controlled innovation.
Precigen (Nasdaq: PGEN), a biopharmaceutical company focused on innovative gene and cell therapies, announced its participation in the 2024 Cantor Global Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, will engage in a fireside chat on September 18, 2024, from 9:45 to 10:15 AM ET in New York.
The conference, scheduled for September 17-19, 2024, provides a platform for Precigen to showcase its advancements in precision medicine. Precigen specializes in developing therapies for immuno-oncology, autoimmune disorders, and infectious diseases using cutting-edge gene and cell therapy technologies. Interested parties can access event details through Precigen's website in the Events & Presentations section.
Precigen (PGEN) reported Q2 and H1 2024 financial results, highlighting key developments for its lead program PRGN-2012 in recurrent respiratory papillomatosis (RRP):
- Pivotal study data showed 51% of RRP patients achieved Complete Response
- Rolling BLA submission anticipated in H2 2024
- Confirmatory trial enrollment initiated
- Appointed new CCO to lead potential 2025 commercial launch
- Raised $31.4M via public offering
The company is prioritizing PRGN-2012 advancement and streamlining other programs. Q2 net loss was $58.8M vs $20.3M in Q2 2023, impacted by $32.9M impairment charge. R&D expenses increased 32% YoY to $15.7M. Cash expected to fund operations into early 2025.
Precigen (Nasdaq: PGEN), a biopharmaceutical company focused on innovative gene and cell therapies, has announced it will release its second quarter and first half 2024 financial results on August 14, 2024. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a business update. Investors can access the call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are advised to dial in 10-15 minutes early. Event details are available on Precigen's website in the Events & Presentations section.
Precigen (Nasdaq: PGEN) has announced the pricing of a public offering of 35,294,118 shares of its common stock at $0.85 per share. The company expects to raise approximately $30.0 million in gross proceeds. Underwriters have a 30-day option to purchase up to an additional 5,294,117 shares. The offering is set to close on August 9, 2024. Precigen plans to use the net proceeds for advancing PRGN-2012 to regulatory approval and commercial readiness, clinical development of other pipeline assets, and for working capital. Combined with recent strategic reprioritization, the funds are expected to support operations into early 2025.
Precigen (Nasdaq: PGEN) has announced a proposed $30 million public offering of its common stock. The company intends to grant underwriters a 30-day option to purchase up to an additional $4.5 million of common stock. Stifel is acting as the sole book-running manager for the offering. The offering is subject to market conditions, and there's no assurance regarding its completion or final terms.
The public offering will be made pursuant to a shelf registration statement on Form S-3, effective since January 17, 2024. A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC. The offering's final terms will be disclosed in a final prospectus supplement to be filed with the SEC.
Precigen (PGEN) announced a strategic reprioritization of its clinical portfolio, focusing on the potential commercialization of PRGN-2012 AdenoVerse® gene therapy for recurrent respiratory papillomatosis (RRP). The company plans to submit a rolling BLA under an accelerated approval pathway in H2 2024, with a potential launch in 2025. Key points include:
- Workforce reduction of over 20%
- Continuation of PRGN-2009 Phase 2 trials with NCI for certain cancers
- Pausing of other UltraCAR-T clinical programs except PRGN-3006 for AML
- Shutdown of ActoBio subsidiary operations
- Pause of all preclinical programs
These changes aim to streamline resources and focus on PRGN-2012's potential commercialization, including BLA submission, confirmatory clinical trial, and manufacturing of commercial product.
Precigen (Nasdaq: PGEN) has appointed Phil Tennant as Chief Commercial Officer to lead commercial strategy and execution for potential launch of PRGN-2012 AdenoVerse gene therapy in recurrent respiratory papillomatosis (RRP). Tennant brings 30+ years of experience from biotech and pharma companies, including Merck, AstraZeneca, Bristol Myers Squibb, and Astellas Pharma. His expertise spans oncology, rare diseases, and global markets. At Astellas, he drove double-digit growth for a $5B oncology portfolio. Tennant will report to CEO Helen Sabzevari and join the executive leadership team, focusing on commercial readiness for PRGN-2012's potential US launch.
Precigen announced positive results from its Phase 1/2 pivotal study for PRGN-2012, a gene therapy for recurrent respiratory papillomatosis (RRP). In the study, 51% of patients achieved complete response, with no surgeries required post-treatment. Additionally, 86% of patients saw reduced surgical interventions. The treatment was well-tolerated, with no severe adverse events reported. The study showed significant improvements in patient quality of life and reduced disease severity. Precigen plans to submit a Biologics License Application (BLA) under an accelerated approval pathway in the second half of 2024, aiming for a potential launch in 2025.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What does Precigen, Inc. specialize in?
What are some of Precigen's core technologies?
What are the key areas of focus for Precigen's therapies?
What recent achievements has Precigen made?
How does Precigen commercialize its technologies?
What makes UltraCAR-T® Cell Therapies unique?
What is the AdenoVerse™ Technology Platform?
Where can I find more information about Precigen's latest updates?
What financial strategies does Precigen employ?
What is the RheoSwitch® Inducible Gene Switch?
